NCT00249405View on ClinicalTrials.gov

Predicting Alcoholics' Treatment Responses to a Selective Serotonin Re-uptake Inhibitor (SSRI)

PHASE2CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions
AlcoholismAlcohol Abuse
Interventions
DRUG

Citalopram + MI

14-week citalopram treatment + Motivational Interview (MI) and 9 brief sessions of a manual-guided Compliance Enhancement Therapy; post-treatment follow-up assessments will be conducted at 4, 12 and 24 weeks.

BEHAVIORAL

Placebo + MI

placebo + single Motivational Interview (MI) and 9 brief sessions of a manual-guided Compliance Enhancement Therapy; post-treatment follow-up assessments will be conducted at 4, 12 and 24 weeks.

Trial Locations (1)

45237

University of Cincinnati, Cincinnati

All Listed Sponsors
collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

lead

University of Cincinnati

OTHER

NCT00249405 - Predicting Alcoholics' Treatment Responses to a Selective Serotonin Re-uptake Inhibitor (SSRI) | Biotech Hunter | Biotech Hunter